ICD Research's ZymoGenetics, Inc.: Company Profile and SWOT Analysis contains in depth information and data about the company and its operations. The profile contains a company overview, business description, financial ratios, competitor benchmarking data, SWOT analysis, key facts, information on products and services, details of locations and subsidiaries, plus information on key news events affecting the company.
This SWOT analysis and company profile is a crucial resource for industry executives and anyone looking to gain a better understanding of the company's business.
ICD Research's ZymoGenetics, Inc.: Company Profile and SWOT Analysis report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format.
ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report.
Examines and identifies key information and issues about ZymoGenetics, Inc. for business intelligence requirements
Studies and presents the company's strengths, weaknesses, opportunities (growth potential) and threats (competition). Strategic and operational business information is objectively reported
Provides analysis on financial ratios along with a competitor benchmarking section
The profile also contains information on business operations, company history, major products and services, prospects, key competitors, key employees, locations and subsidiaries
Reasons To Buy
Quickly enhance your understanding of the company
Gain insight into the marketplace and a better understanding of internal and external factors which could impact the industry
Increase business/sales activities by understanding your competitors’ businesses better
Recognize potential partnerships and suppliers
Obtain yearly profitability figures
ZymoGenetics, Inc. (ZymoGenetics) is a biotechnology company engaged in the development and commercialization of therapeutic proteins for the treatment of human diseases. The company’s development programs are principally focused on hemostasis, cancer, viral infections, inflammatory and autoimmune diseases. ZymoGenetics portfolio of products comprised of a commercial product, RECOTHROM Thrombin, topical (Recombinant), and three immunology product candidates, namely, PEG-IFN-lambda, IL-21, and IL-31 mAb. Further, its out-licensed product candidates comprise of Atacicept, Augment, rFactor XIII, FGF-18, IL-17RC, IL-20, IL-22RA and IL-21 mAb. Similarly, the company’s out licensed commercial products portfolio consists of Novolin, NovoSeven, Regranex, GEM 21S, GlucaGen, and Cleactor. The company is headquartered in Seattle, Washington, the US.